These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 29618084)

  • 1. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
    Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
    McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
    Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
    Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.
    Raychaudhuri SP; Shah RJ; Banerjee S; Raychaudhuri SK
    Curr Rheumatol Rep; 2024 Jun; 26(6):204-213. PubMed ID: 38492148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
    Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
    Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
    Bechman K; Yates M; Galloway JB
    Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
    Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2017 Jul; 29(4):311-316. PubMed ID: 28394822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review.
    Jubber A; Tahir H; Moorthy A
    Musculoskeletal Care; 2023 Dec; 21(4):1195-1203. PubMed ID: 37501580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
    O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
    Front Immunol; 2021; 12():672461. PubMed ID: 34248953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatment options for spondyloarthritis.
    Torgutalp M; Poddubnyy D
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.